CL2020002398A1 - Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") - Google Patents
Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")Info
- Publication number
- CL2020002398A1 CL2020002398A1 CL2020002398A CL2020002398A CL2020002398A1 CL 2020002398 A1 CL2020002398 A1 CL 2020002398A1 CL 2020002398 A CL2020002398 A CL 2020002398A CL 2020002398 A CL2020002398 A CL 2020002398A CL 2020002398 A1 CL2020002398 A1 CL 2020002398A1
- Authority
- CL
- Chile
- Prior art keywords
- triazacyclododecanesulfonamide
- tcd
- based protein
- protein secretion
- secretion inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 230000028327 secretion Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101100476756 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) sec-61 gene Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención describe inhibidores de la secreción de proteínas basados en triazaciclododecansulfonamida ("TCD"), tales como inhibidores de Sec61, métodos para su preparación, composiciones farmacéuticas relacionadas y métodos para usar los mismos. Por ejemplo, describe compuestos de Fórmula (I) y sales y composiciones farmacéuticamente aceptables que incluyen las mismas. Los compuestos descritos aquí pueden usarse en el tratamiento de enfermedades que incluyen inflamación y/o cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643931P | 2018-03-16 | 2018-03-16 | |
| US201962803704P | 2019-02-11 | 2019-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002398A1 true CL2020002398A1 (es) | 2021-02-12 |
Family
ID=66041635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002398A CL2020002398A1 (es) | 2018-03-16 | 2020-09-16 | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US11578055B2 (es) |
| EP (1) | EP3765447B1 (es) |
| JP (1) | JP2021518337A (es) |
| KR (1) | KR102838413B1 (es) |
| CN (1) | CN112262129B (es) |
| AU (1) | AU2019236248B2 (es) |
| BR (1) | BR112020018767A2 (es) |
| CA (1) | CA3093972A1 (es) |
| CL (1) | CL2020002398A1 (es) |
| CO (1) | CO2020012484A2 (es) |
| DK (1) | DK3765447T3 (es) |
| ES (1) | ES2953139T3 (es) |
| FI (1) | FI3765447T3 (es) |
| HR (1) | HRP20230804T1 (es) |
| HU (1) | HUE062455T2 (es) |
| IL (1) | IL277252B2 (es) |
| JO (1) | JOP20200233B1 (es) |
| LT (1) | LT3765447T (es) |
| MA (1) | MA52008A (es) |
| MX (1) | MX2020009645A (es) |
| MY (1) | MY203877A (es) |
| PE (1) | PE20210926A1 (es) |
| PH (1) | PH12020551493A1 (es) |
| PL (1) | PL3765447T3 (es) |
| PT (1) | PT3765447T (es) |
| RS (1) | RS64524B1 (es) |
| SA (1) | SA520420147B1 (es) |
| SG (1) | SG11202008841VA (es) |
| SI (1) | SI3765447T1 (es) |
| SM (1) | SMT202300247T1 (es) |
| TW (1) | TWI818962B (es) |
| WO (1) | WO2019178510A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116199618A (zh) * | 2022-12-30 | 2023-06-02 | 深圳市江川医药技术有限公司 | 一种高产率高纯度合成氟哌啶醇杂质e的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663161A (en) * | 1995-02-17 | 1997-09-02 | The Research Foundation Of State University Of New York | Anti-viral triaza compounds |
| US5724868A (en) * | 1996-01-11 | 1998-03-10 | Buck Knives, Inc. | Method of making knife with cutting performance |
| WO2002080856A2 (en) * | 2001-04-06 | 2002-10-17 | University And Community College System Of Nevada On Behalf Of The University Of Nevada, Reno | Triaza compound immunoregulatory agents |
-
2019
- 2019-03-15 MY MYPI2020004809A patent/MY203877A/en unknown
- 2019-03-15 PT PT197156094T patent/PT3765447T/pt unknown
- 2019-03-15 SM SM20230247T patent/SMT202300247T1/it unknown
- 2019-03-15 JP JP2020548935A patent/JP2021518337A/ja active Pending
- 2019-03-15 DK DK19715609.4T patent/DK3765447T3/da active
- 2019-03-15 TW TW108108893A patent/TWI818962B/zh active
- 2019-03-15 AU AU2019236248A patent/AU2019236248B2/en active Active
- 2019-03-15 HR HRP20230804TT patent/HRP20230804T1/hr unknown
- 2019-03-15 WO PCT/US2019/022533 patent/WO2019178510A1/en not_active Ceased
- 2019-03-15 CA CA3093972A patent/CA3093972A1/en active Pending
- 2019-03-15 SI SI201930602T patent/SI3765447T1/sl unknown
- 2019-03-15 PE PE2020002281A patent/PE20210926A1/es unknown
- 2019-03-15 BR BR112020018767-4A patent/BR112020018767A2/pt not_active Application Discontinuation
- 2019-03-15 KR KR1020207029261A patent/KR102838413B1/ko active Active
- 2019-03-15 IL IL277252A patent/IL277252B2/en unknown
- 2019-03-15 SG SG11202008841VA patent/SG11202008841VA/en unknown
- 2019-03-15 MX MX2020009645A patent/MX2020009645A/es unknown
- 2019-03-15 LT LTEPPCT/US2019/022533T patent/LT3765447T/lt unknown
- 2019-03-15 MA MA052008A patent/MA52008A/fr unknown
- 2019-03-15 US US16/979,457 patent/US11578055B2/en active Active
- 2019-03-15 HU HUE19715609A patent/HUE062455T2/hu unknown
- 2019-03-15 FI FIEP19715609.4T patent/FI3765447T3/fi active
- 2019-03-15 CN CN201980032763.5A patent/CN112262129B/zh active Active
- 2019-03-15 PL PL19715609.4T patent/PL3765447T3/pl unknown
- 2019-03-15 RS RS20230647A patent/RS64524B1/sr unknown
- 2019-03-15 EP EP19715609.4A patent/EP3765447B1/en active Active
- 2019-03-15 ES ES19715609T patent/ES2953139T3/es active Active
-
2020
- 2020-09-15 JO JOJO/P/2020/0233A patent/JOP20200233B1/ar active
- 2020-09-15 PH PH12020551493A patent/PH12020551493A1/en unknown
- 2020-09-16 SA SA520420147A patent/SA520420147B1/ar unknown
- 2020-09-16 CL CL2020002398A patent/CL2020002398A1/es unknown
- 2020-10-06 CO CONC2020/0012484A patent/CO2020012484A2/es unknown
-
2022
- 2022-05-11 US US17/741,989 patent/US12600711B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2024001022A1 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| CL2021000907A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020) | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| NI201900062A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| CO2019009722A2 (es) | Dendrímeros terapéuticos | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
| MX389962B (es) | Metodos para tratar trastornos mitocondriales y metabolicos. | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| MX2018007511A (es) | Compuestos de alquinil dihidroquinolina sulfonamida. | |
| EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| UY37745A (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
| CO2020012484A2 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| MX2019007950A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa. | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 |